Repligen Co. (NASDAQ:RGEN) CEO Anthony Hunt sold 12,094 shares of the business’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $82.40, for a total value of $996,545.60. Following the completion of the transaction, the chief executive officer now owns 210,976 shares in the company, valued at $17,384,422.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
RGEN stock traded down $0.69 during mid-day trading on Wednesday, hitting $79.88. The company had a trading volume of 1,073,938 shares, compared to its average volume of 461,140. The company has a market capitalization of $4.18 billion, a price-to-earnings ratio of 109.42, a P/E/G ratio of 4.82 and a beta of 1.16. Repligen Co. has a 12-month low of $48.26 and a 12-month high of $99.25. The company has a quick ratio of 1.88, a current ratio of 2.25 and a debt-to-equity ratio of 0.02. The company has a 50-day moving average price of $91.47 and a 200 day moving average price of $74.32.
Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Thursday, August 1st. The biotechnology company reported $0.31 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.25 by $0.06. Repligen had a return on equity of 6.92% and a net margin of 11.42%. The firm had revenue of $70.70 million during the quarter, compared to analyst estimates of $65.47 million. During the same quarter last year, the business posted $0.14 earnings per share. The business’s quarterly revenue was up 48.1% compared to the same quarter last year. As a group, analysts expect that Repligen Co. will post 0.97 EPS for the current year.
Several analysts recently issued reports on RGEN shares. Craig Hallum increased their target price on Repligen from $80.00 to $108.00 and gave the stock a “buy” rating in a research report on Monday, August 5th. Stephens reissued an “overweight” rating and set a $110.00 target price on shares of Repligen in a research note on Thursday, August 22nd. ValuEngine cut Repligen from a “strong-buy” rating to a “buy” rating in a report on Thursday, August 1st. First Analysis upped their price target on Repligen from $95.00 to $107.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 28th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $110.00 price objective on shares of Repligen in a report on Monday, August 12th. One investment analyst has rated the stock with a hold rating and ten have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $101.17.
Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.
Featured Article: What are the Benefits of Index Funds?
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.